Abstract Library

#3172 Peptide receptor radionuclide therapy (PRRT) with Lu-DOTATATE following liver directed therapy (LDT) in neuroendocrine tumors (NETs): Hepatotoxicity and impact on progression-free survival (PFS)

Introduction: PRRT (Lu-DOTATATE) and LDT (e.g. hepatic artery embolization) are commonly used in treating liver dominant NETs. Hepatotoxicity from PRRT in the setting of metastatic disease and prior liver-directed therapy is an important consideration. There is a concern for hepatotoxicity in patients receiving PRRT based on the literature, but there is limited data on patients who may have had a prior liver injury from LDT.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Badawy M

Authors: Badawy M, Halfdanarson T, Johnson G, Hobday T, Young J,

Keywords: hepatotoxicity, PRRT (LU-DOTATATE), liver targeted therapy, progression-free survival, NEN, NET,

#2881 Patient-Derived Tumor Xenograft Combined with Chemotherapy Drug Sensitivity Test in a Patient with Pancreatic Neuroendocrine Carcinoma

Introduction: Pancreatic neuroendocrine carcinoma (p-NEC) with liver metastasis has a poor prognosis. The treatment is mainly chemotherapy which is now still a huge challenge on NEC with high ki-67 index.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Bai J

Authors: Bai J, Tang Q,

Keywords: Pancreatic neuroendocrine carcinoma, chemotherapy, Doxorubicin+mitomycin+loplatin, patient-derived tumor xenograft, Carbon ion,

#457 Comparison of Transarterial Liver-Directed Therapies (LDT) for Low-Grade Metastatic Neuroendocrine Tumors (mNETs)

Introduction: Transarterial LDT can ameliorate symptoms and improve time to tumor progression (TTP) in mNETs.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Engelman E, Leon-Ferre R, Naraev B, Sharma N, Sun S,

Keywords: hepatic, artery, embolization, chemoembolization, radioembolization, neuroendocrine, tumors,

#211 Phase II Study of Sunitinib Following Hepatic Transarterial Embolization for Metastatic Neuroendocrine Tumors

Introduction: Hepatic transarterial embolization is often recommended for patients with liver-predominant metastatic NETs. Antiangiogenic therapy following embolization may delay tumor revascularization.

Conference: 8th Annual ENETSConcerence (2011)

Presenting Author:

Authors: Strosberg J, Cheema A, Campos T, Kvols L,

Keywords: transarterial embolization, sunitinib, progression-free survival,

#77 Angiogenesis markers after hepatic artery embolization of liver metastases in patients with neuroendocrine tumors

Introduction: In the event of diffuse hepatic metastases, hepatic artery embolization (HAE) can be a successful treatment option in patients with well-differentiated neuroendocrine tumors (WNET). Although there are suggestions of activation of the angiogenesis by HAE, no information is available about the development of growth factors caused by vascular obstruction with embolization.

Conference: 7th Annual ENETSConcerence (2010)

Presenting Author:

Authors: Korse C, Bonfrer J, Taal B,

Keywords: neuroendocrine tumors, hepatic artery embolization, angiogenesis, necrosis, VEGF, Endothelin, pro-Endothelin, cytokeratin, MonoTotal,